Document is current
Any future updates will be listed below
-
Authors
Weinmayr, Gudrun
Schulz, Holger
Klenk, Jochen https://orcid.org/0000-0002-5987-447X
Denkinger, Michael
Duran-Tauleria, Enric
Koenig, Wolfgang https://orcid.org/0000-0002-2064-9603
Dallmeier, Dhayana
Rothenbacher, Dietrich https://orcid.org/0000-0002-3563-2791
,
Böhm, B.
Geiger, H.
Laszlo, R.
Steinacker, J. M.
Ludolph, A.
von Arnim, C.
Lukas, A.
Peter, R.
Rapp, K.
Riepe, M.
Scharffetter-Kochanek, K.
Stingl, J.
-
Funding
Funding for this research was provided by:
National Institutes of Health (R01HL138490, R01HL138490)
Wellstone Muscular Dystrophy Specialized Research Center (1U54NS053672, 1U54NS053672)
- License Information
-
More Information
Article History
Received: 28 May 2019
Accepted: 18 June 2020
First Online: 17 July 2020
Competing interests
: Dr. Koenig reports personal fees (consulting) from AstraZeneca, Novartis, Pfizer, The Medicines Company, DalCor, Kowa, Amgen, Corvidia, Daiichi-Sankyo; personal fees (honorarium for lectures) from AstraZeneca, Novartis, Amgen, Berlin-Chemie, Sanofi, Bristol-Myers Sqibb; grants and non-financial support (provision of reagents for biomarker measurements free of charge) from Roche Diagnostics, Beckmann, Singulex, and Abbott, outside the submitted work; The other authors declare no competing interests.
